Aytu BioScience

Aytu BioPharma has revised several warrants from June 2023 and June 2025 because original lock-up provisions had caused them to be recorded as liabilities under ASC 480/815. The amendments are intended to reduce liabilities on the balance sheets and correspondingly increase equity. The company also notes that the amended instruments are not registered under the Securities Act and separately reports a decline in revenue and margins in the second quarter of 2026, as well as a net loss that has worried investors. » Plus sur de.investing.com

Aytu BioPharma reported a net revenue decline to $15.2 million in Q2 2026 (prior year $16.2 million) and a reduced gross margin from 66.5% to 63.5%, resulting in a net loss of $10.6 million. Shares fell 3.32% in after-hours trading. The company is launching EXXUA for the treatment of major depressive disorder and targets cash breakeven at $16.6 million in quarterly revenue (total breakeven $17.3 million). Aytu holds $30 million in cash and expects operating expenses of $4–5 million in the coming quarter with a year-end target of $11.6 million. » Plus sur de.investing.com

Aytu BioPharma has launched EXXUA — the first FDA‑approved selective 5‑HT1A agonist for the treatment of major depressive disorder in adults — nationwide in retail and Aytu‑RxConnect pharmacies. The once‑daily medication is now commercially available following the launch meeting and sales and distribution trainings. Aytu is a micro‑cap with a market capitalization of $27.1 million; the stock rose 55.1% last year according to InvestingPro, and analyst targets range from $7 to $13 versus the current price of $2.66. EXXUA carries a boxed warning for increased suicide risk in younger patients and has several contraindications and recommended dosing limits. » Plus sur de.investing.com